As market tanked globally, I think it might be one of the better...

As market tanked globally, I think it might be one of the better times to buy mesoblast, before its FDA decision.
The inherent risk obviously is the outcome of FDA and the subsequent market traction of its product.

However, give its market cap about $1.1bn AUD, with the advance of its technlogy (compared to its global peers) with three phase-three stem-cell treatment and a web of patents. I think it can potentially rival the status of CSL, as a global biotech firm.

For the weekend, just want to share some light video material about patient review on Mesoblast treatment.
Personally, I think its science and stem-cell treatments are absolutely solid and life-saving, especially for conditions, which conventional standard of care could not treat. It would be a loss to people, if its treatment does not get FDA and other approvals to benefit more patients globally.